Lesaffre completes full acquisition of Gnosis

By Nathan Gray

- Last updated on GMT

Lesaffre completes full acquisition of Gnosis
Global fermentation player Lesaffre has completed the full acquisition of Italian biotechnology specialist Gnosis three years after its acquired a majority shareholding in the firm.

The deal will see Italy-based Gnosis combine with Lesaffre Human Care business unit, creating a single unit with a unified range of products and services in nutritional ingredients and human health.

"For the past three years, we have developed the cooperation between Lesaffre and Gnosis teams to become today a unique provider of products and services that are increasingly innovative and closely address our customer’s needs in the Nutrition and Health sectors,” ​commented Antoine Baule, Lesaffre's Chief Executive Officer.

I would like to thank Renzo Berna, former CEO of Gnosis, for his relentless dedication to building a successful company, and my respect for the great accomplishment of his purpose.”

Italian biotechnology specialist Gnosis, meanwhile, specializes in the development, manufacturing and sale of fermentation-derived ingredients and natural finished products for use in the pharmaceutical, nutraceutical, veterinary and cosmetic industries.

Lesaffre created its nutrition unit, Lesaffre Human Care, in 20017. Its mission has been to develop and supply ingredients from yeast and bacteria fermentation to the global human care industries.

From nutritional and fortified yeasts to yeast fractions, probiotic yeasts and bacteria, or pure molecules, Lesaffre Human Care targets a wide range of applications: digestive health, immunity enhancement, joints and liver health, woman’s health vegetarian support, overall wellbeing and personal care.

Gnosis owns two GMP manufacturing sites (Sant Antonino in Switzerland and Pisticci in Italy) and two commercial offices (USA and China). Its offices and R&D facility are based at Desio, near Milan.

Renzo Berna, former CEO of Gnosis said developing the company has been an ‘exciting challenge’.

“After 25 years, Gnosis has become a reference on the market able to design and manufacture fermentation purified metabolites as health care active ingredients for the nutraceutical and pharmaceutical markets,” ​he added.

“I am convinced that Lesaffre, a family group known and recognised internationally for its professionalism and the quality of its products and services will take this company even further forwards."

Related topics Suppliers

Related news

Follow us


View more